AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


Features


Controversies remain about the efficacy of CYP2C19 guided antiplatelet therapy for patients who have had percutaneous intervention, but 12 hospitals in the IGNITE network adopted this approach, bringing positive patient outcomes and satisfaction to clinicians. They shared the secrets of their success with CLN.
Experts agree there still is plenty of room for innovation in clinical chemistry. From harnessing the power of data to the discovery of new biomarkers, this field is advancing rapidly, and vendors are still investing heavily in the latest technologies.

Ask the Expert


Although oxytocin testing has not yet become a routine clinical assay, in the future it could aid healthcare providers in assessing behavioral, psychiatric, and stress-related conditions

Bench Matters


Repeating tests that yield critical results before reporting them out is a long-standing practice in clinical laboratories. But is the extra step, which takes time and lab resources, necessary given the robust analytical performance of modern instruments? Lab professionals at Cleveland Clinic weigh in on this controversial procedure.

Federal Insider


Industry Playbook


Laboratory Stewardship


Daniel Anderson, MD, and Michael Astion, MD, PhD, interviewed medical geneticist and thought leader Matthew Fickie, MD, FACMG, of Highmark Health in Pittsburgh, about the chal-lenges of third-party payer management of laboratory testing.
Genetic testing in the perimortem period—immediately before or after a patient’s death—involves unique ethical and logistical issues in pediatric hospitals. Genetic testing may be nec-essary to confirm an underlying diagnosis, yet testing may not be medically necessary because the results will not change medical care for the child.

Regulatory Roundup


The Food and Drug Administration (FDA) has cleared Bio-Rad Laboratories’ QXDx BCR-ABL %IS kit and QXDx AutoDG ddPCR system for monitoring chronic myeloid leukemia (CML) pa-tients’ molecular response to treatment. This test uses Bio-Rad’s droplet digital polymerase chain reaction (ddPCR) technology and is the first digital PCR test to receive…

The Sample